PDG35 COST-EFFECTIVENESS ANALYSIS OF LOW-DOSE RIVAROXABAN PLUS ASPIRIN FOR THE PATIENTS WITH STABLE CARDIOVASCULAR DISEASE IN TAIWAN SETTING

May 1, 2019, 00:00
10.1016/j.jval.2019.04.714
https://www.valueinhealthjournal.com/article/S1098-3015(19)30906-4/fulltext
Title : PDG35 COST-EFFECTIVENESS ANALYSIS OF LOW-DOSE RIVAROXABAN PLUS ASPIRIN FOR THE PATIENTS WITH STABLE CARDIOVASCULAR DISEASE IN TAIWAN SETTING
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)30906-4&doi=10.1016/j.jval.2019.04.714
First page :
Section Title :
Open access? : No
Section Order : 10310
Categories :
Tags :
Regions :
ViH Article Tags :